Table 2.
Various antiviral drugs and their mechanism of action.
| Virus | Drug | Mechanism of action | Reference |
|---|---|---|---|
| Ebola | mAb114 | Rojas et al. (2019) | |
| HIV | Zidovudine | Nucleoside reverse transcriptase Inhibitor | Justice et al. (2004) |
| Nevirapine | Nonnucleoside reverse transcriptase Inhibitor | Jiang et al. (2014) | |
| Ritonavir | Protease inhibitor | Chen et al. (2005) | |
| Enfuvirtide | Entry (Fusion) inhibitor | Wnuk (2008) | |
| Raltegravir | Integrase inhibitor | Taramasso et al. (2015) | |
| Maraviroc | CCR5 receptor inhibitor | Armstrong-James et al. (2010) | |
| SARS- CoVs | Ribavirin | Decrease intracellular guanosine triphosphate which results in inhibition of caps of viral transcripts, suppress cellular and humoral immune response | (Cameron and Castro, 2001; Peiris et al., 2003) |
| Lopinavir (LPV) + Ritonavir (R) | R helps in inhibiting CYP3A4 metabolism of LPV and increased LPV serum conc. | Chu et al. (2004) | |
| Methylprednisolone | Help in decreasing cytokine storm (ILs, and TNF) | Smego and Ahmed (2003) | |
| ZIKA | Chloroquine | Inhibitory effect against early stages of ZIKA Virus in mice |
Li et al. (2017) Devaux et al. (2020) |